StemCyte International, Ltd. Stock Price

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy. Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies. The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. operates as a subsidiary of Diamond Biofund Inc.